Add BrightSurf on Google Email

ASH 2026 Tip Sheet: Sylvester researchers contribute to dozens of oral presentations at American Society of Hematology Annual Meeting

Sylvester researchers made significant contributions to various oral presentations at the American Society of Hematology Annual Meeting, including results from phase 2 trials for multiple myeloma and lymphoma treatments. The studies showcased promising efficacy and safety profiles for novel immunotherapies.

Vienna research team reveals how RNA molecules influence the development of aggressive leukemia

A new study reveals how RNA molecules, particularly lncRNA Gas5, influence the development of aggressive leukemia by forming biomolecular condensates. The research identifies several long non-coding RNAs associated with these structures and shows that Gas5 plays a key role in leukemia cell proliferation.

SourceCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences·JournalThe EMBO Journal·TypeExperimental study·DateOct 14, 2026

Even highly curable childhood cancers take a substantial toll on families, according to new study from JNCCN

Families of children with B-cell acute lymphoblastic leukemia (B-ALL) experience substantial and lasting challenges, including household employment changes and marital status changes, beginning early after diagnosis. These challenges persist throughout treatment and have significant financial, social, and emotional impacts on families.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateOct 13, 2026

New method causes cancer cells to burn out

Researchers developed a new treatment for acute myeloid leukemia (AML) by using AcTor, a molecule that inhibits a signalling protein, in combination with ixazomib. The treatment successfully eliminated cancer cells and leukemic stem cells, showing promising results in mice studies.

SourceUniversity of Gothenburg·JournalMolecular Cancer·TypeExperimental study·DateSep 8, 2026

Mass General Brigham-led trial shows a less-intensive drug combination is more effective in treating AML

A phase 2 clinical trial found that a less-intensive combination of azacitidine and venetoclax was more effective in treating acute myeloid leukemia, with patients tolerating treatment better and spending less time in the hospital. The combination also led to more patients reaching stem cell transplantation.

SourceMass General Brigham·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateSep 2, 2026

Investment in blood cancer research has saved nearly 26 million years of life, but major gaps in survival remain

Advances in blood cancer treatment have saved 25.8 million life-years, with significant gains for Hodgkin lymphoma and non-Hodgkin lymphoma patients. However, Black patients and those with acute myeloid leukemia (AML) continue to experience worse outcomes, highlighting the need for continued research investment.

SourceAmerican Society of Hematology·JournalBlood Advances·DateSep 1, 2026

Protective drug dexrazoxane reduces heart damage in pediatric cancer survivors years after treatment ends

A large study reveals that dexrazoxane significantly reduces heart damage caused by chemotherapy in pediatric cancer patients years after treatment. The findings could change how doctors follow survivors for decades and provide families with reassurance about long-term effects.

SourceUniversity of Florida·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateAug 7, 2026

City of Hope shows outreach to bone marrow transplant survivors and their primary care doctors can markedly cut skin cancer risk

A new study published in JNCCN finds that a cost-effective education program targeting survivors and their doctors can increase screening rates for skin cancer. The study showed that practical solutions can close the gap between elevated risks and low screening rates, especially after transitioning out of specialty care.

SourceCity of Hope·JournalJournal of the National Comprehensive Cancer Network·DateAug 6, 2026

Immune cells use previously unknown pathway to eliminate AML

Scientists at MD Anderson Cancer Center have identified a previously unknown mechanism by which T cells attack and eliminate acute myeloid leukemia (AML) cells. The discovery reveals that AML cells use a CD64-dependent pathway to evade traditional MHC recognition, potentially explaining why AML is sensitive to immune-based treatments.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalProceedings of the National Academy of Sciences·DateJul 15, 2026

Epigenetic therapy shows promise against treatment-resistant AML

Researchers discovered a new epigenetic therapy that remained effective in treatment-resistant acute myeloid leukemia (AML) through activating the Hippo pathway, a tumor-suppressing pathway linked to cancer growth and drug resistance. The therapy, NTX-301, consistently reduced leukemia cell survival more effectively than existing hypom...

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalClinical Cancer Research·DateJul 13, 2026

IU study finds obesity 'fuels' leukemia, but a combo using popular weight-loss drugs may stop it

Researchers identified a potential new treatment strategy combining popular weight-loss medications with anti-inflammatory drugs to help patients with obesity-associated leukemia. The study found that obesity creates a state of chronic inflammation that accelerates the growth of mutated, leukemia-causing blood stem cells.

SourceIndiana University·JournalJournal of Clinical Investigation·DateJul 13, 2026

Heterogeneous phenotype of acute leukemia with EWSR1 or FUS gene rearrangements

Acute leukemias with EWSR1 or FUS gene rearrangements display heterogeneous clinical and pathological characteristics. Cytogenetic karyotyping and fluorescence in situ hybridization remain crucial tools for detecting chromosomal translocations, while advanced molecular diagnostic methods are recommended to improve accurate diagnosis.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Pathology·DateJun 27, 2026

New molecular tool transforms how clinicians classify and treat a rare blood cancer

Researchers developed a novel disease classification system and AI-assisted decision support tool to improve CMML care. The International CMML Prognostic Scoring System (iCPSS) demonstrates superior prognostic discrimination, stratifying patients into five risk groups with different survival outcomes.

SourceJosep Carreras Leukaemia Research Institute·JournalJournal of Clinical Oncology·TypeExperimental study·DateApr 29, 2026